Drug
Lerociclib clinical trials
Also written G1T38.
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
G1 Therapeutics, Inc. (3) · Genor Biopharma Co., Ltd. (2) · EQRx International, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lerociclib is read from its arms, and is right about nine times in ten.
Testing it · 6
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedPhase 3Genor Biopharma Co., Ltd.NCT05054751Written as GB491+ Fulvestrant
- Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial CancerWithdrawnPhase 3EQRx International, Inc.NCT05712941Written as Lerociclib
- G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedPhase 1/2G1 Therapeutics, Inc.NCT03455829Written as G1T38
- G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownPhase 1/2G1 Therapeutics, Inc.NCT02983071Written as G1T38
- A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast CancerStatus unknownPhase 1Genor Biopharma Co., Ltd.NCT05337657Written as GB491+Letrozole
- First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy VolunteersCompletedPhase 1G1 Therapeutics, Inc.NCT02821624Written as G1T38 (CDK 4/6 Inhibitor)
Codes
What other systems call lerociclib · ClinicalTrials.gg INT018341
- UNII (FDA) WBH8AY6ENBLEROCICLIBConfirmed FDA, Wikidata
- Wikidata Q105337326lerociclibConfirmed FDA, Wikidata
- NCI Thesaurus C138165LerociclibOne source FDA
- DrugBank DB16218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WBH8AY6ENB | LEROCICLIB | Confirmed FDA, Wikidata |
| Wikidata | Q105337326 | lerociclib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C138165 | Lerociclib | One source FDA |
| DrugBank | DB16218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.